Funding for this research was provided by:
National Institutes of Health (S10OD010650, S10OD023503, S10OD025234)
Received: 23 April 2021
Accepted: 1 July 2021
First Online: 8 July 2021
: Not applicable.
: All authors reviewed and agreed with the publication of this manuscript in this journal.
: Zdravka Medarova is Founder and has equity in TransCode Therapeutics, Inc. Peter Caravan has equity in Reveal Pharmaceuticals. He has equity in and is a consultant to Collagen Medical LLC. Peter Caravan has research support from Pliant Therapeutics, Indalo Therapeutics, Celgene, Takeda, and Janssen. None of these interests are related to this work.